Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development
Clinical Trials
Vamorolone is in clinical testing for Duchenne Muscular Dystrophy (NCT05185622) and Becker Muscular Dystrophy (NCT05166109).
Learn more >
About vamorolone
Vamorolone is being reviewed for approval in the US, EU, and UK for treatment of DMD.
Learn More >Research
Vamorolone shows efficacy in Duchenne Muscular Dystrophy and safety advantages over prednisone (Guglieri et al. 2022).
Learn More >News
Pratteln, Switzerland, and Rockville, MD, USA, April 25, 2023
Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting by the U.S. Food and Drug Administration (FDA) of the new drug application (NDA)
